313 related articles for article (PubMed ID: 36202661)
1. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
de Boer IH; Khunti K; Sadusky T; Tuttle KR; Neumiller JJ; Rhee CM; Rosas SE; Rossing P; Bakris G
Kidney Int; 2022 Nov; 102(5):974-989. PubMed ID: 36202661
[TBL] [Abstract][Full Text] [Related]
2. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
de Boer IH; Khunti K; Sadusky T; Tuttle KR; Neumiller JJ; Rhee CM; Rosas SE; Rossing P; Bakris G
Diabetes Care; 2022 Dec; 45(12):3075-3090. PubMed ID: 36189689
[TBL] [Abstract][Full Text] [Related]
3. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.
Navaneethan SD; Zoungas S; Caramori ML; Chan JCN; Heerspink HJL; Hurst C; Liew A; Michos ED; Olowu WA; Sadusky T; Tandon N; Tuttle KR; Wanner C; Wilkens KG; Craig JC; Tunnicliffe DJ; Tonelli M; Cheung M; Earley A; Rossing P; de Boer IH; Khunti K
Ann Intern Med; 2023 Mar; 176(3):381-387. PubMed ID: 36623286
[TBL] [Abstract][Full Text] [Related]
4. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.
de Boer IH; Caramori ML; Chan JCN; Heerspink HJL; Hurst C; Khunti K; Liew A; Michos ED; Navaneethan SD; Olowu WA; Sadusky T; Tandon N; Tuttle KR; Wanner C; Wilkens KG; Zoungas S; Lytvyn L; Craig JC; Tunnicliffe DJ; Howell M; Tonelli M; Cheung M; Earley A; Rossing P
Kidney Int; 2020 Oct; 98(4):839-848. PubMed ID: 32653403
[TBL] [Abstract][Full Text] [Related]
5. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.
Mottl AK; Alicic R; Argyropoulos C; Brosius FC; Mauer M; Molitch M; Nelson RG; Perreault L; Nicholas SB
Am J Kidney Dis; 2022 Apr; 79(4):457-479. PubMed ID: 35144840
[TBL] [Abstract][Full Text] [Related]
6. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.
Rossing P; Caramori ML; Chan JCN; Heerspink HJL; Hurst C; Khunti K; Liew A; Michos ED; Navaneethan SD; Olowu WA; Sadusky T; Tandon N; Tuttle KR; Wanner C; Wilkens KG; Zoungas S; Craig JC; Tunnicliffe DJ; Tonelli MA; Cheung M; Earley A; de Boer IH
Kidney Int; 2022 Nov; 102(5):990-999. PubMed ID: 36272755
[TBL] [Abstract][Full Text] [Related]
7. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
Shubrook JH; Neumiller JJ; Wright E
Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
[TBL] [Abstract][Full Text] [Related]
8. How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Smetana GW; Romeo GR; Rosas SE; Burns RB
Ann Intern Med; 2024 Jun; 177(6):800-811. PubMed ID: 38857499
[TBL] [Abstract][Full Text] [Related]
9. Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease.
Neumiller JJ; Alicic RZ; Tuttle KR
Semin Nephrol; 2023 May; 43(3):151427. PubMed ID: 37857231
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
11. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.
Nee R; Yuan CM; Narva AS; Yan G; Norris KC
Nephrol Dial Transplant; 2023 Feb; 38(3):532-541. PubMed ID: 36264305
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week.
Morales J; Handelsman Y
J Am Coll Cardiol; 2023 Jul; 82(2):161-170. PubMed ID: 37407115
[TBL] [Abstract][Full Text] [Related]
13. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
[TBL] [Abstract][Full Text] [Related]
14. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
Diabetologia; 2018 Dec; 61(12):2461-2498. PubMed ID: 30288571
[TBL] [Abstract][Full Text] [Related]
15. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
16. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
17. [New guideline on diabetes management in chronic kidney disease].
Wanner C; Busch M
Inn Med (Heidelb); 2023 Mar; 64(3):219-224. PubMed ID: 36745249
[TBL] [Abstract][Full Text] [Related]
18. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD.
Mottl AK; Nicholas SB
Am J Kidney Dis; 2024 Mar; 83(3):277-287. PubMed ID: 38142396
[TBL] [Abstract][Full Text] [Related]
19. Cardiorenal disease management in type 2 diabetes: An expert consensus.
Mohan V; Singh AK; Zargar AH; Almeida A; Bhalla AK; Mohan JC; Dalal J; Sahay M; Mohanan PP; Maitra S; Ghosh S; Jeloka T; Kaul U; Sakhuja V; Das MK
Diabetes Metab Syndr; 2022 Dec; 16(12):102661. PubMed ID: 36375366
[TBL] [Abstract][Full Text] [Related]
20. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
DeFronzo RA; Bakris GL
Diabetes Obes Metab; 2022 Jul; 24(7):1197-1205. PubMed ID: 35302284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
